Attached files

file filename
EX-32.2 - CERTIFICATION - ABVC BIOPHARMA, INC.f10k2016ex32ii_american.htm
EX-31.2 - CERTIFICATION - ABVC BIOPHARMA, INC.f10k2016ex31ii_american.htm
EX-31.1 - CERTIFICATION - ABVC BIOPHARMA, INC.f10k2016ex31i_american.htm
EX-10.3 - EMPLOYMENT AGREEMENT WITH KIRA HUANG - ABVC BIOPHARMA, INC.f10k2016ex10iii_american.htm
10-K - ANNUAL REPORT - ABVC BIOPHARMA, INC.f10k2016_americanbrivision.htm

Exhibit 32.1

 

CERTIFICATION OF DISCLOSURE PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of American BriVision (Holding) Corporation (the "Company") on Form 10-K for the year endeded September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report") I, Eugene Jiang, Chief Executive Officer of the Company, certify, pursuant to 18 USC section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: January 12, 2017

 

 

By: /s/ Eugene Jiang

 

Eugene Jiang

Chief Executive Officer

(Principal Executive Officer)

 

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.